论文部分内容阅读
目的:探讨埃克替尼对非小细胞肺癌(non-small cell lung cancer,NSCLC)EGFR 18外显子G719X/E709X/G724S的临床疗效。方法:回顾性分析24例埃克替尼治疗EGFR18外显子少见突变的NSCLC患者,服用至病情进展或出现不可耐受的毒副作用,比较疗效。结果:24例G719X/E709X/G724S突变患者中G719X突变19例,中位无进展生存时间2.8个月,E709X突变3例,中位无进展生存时间3.1个月,G724S突变2例,中位无进展生存时间3.5个月。G724S突变患者生存时间稍长。复合突变与单纯突变相比,复合突变中位无进展生存时间更长(G719X突变3.3个月vs.2.6个月,P=0.029;E709X突变7.2个月vs.2.7个月,P=0.225)。结论:埃克替尼在EGFR基因18外显子少见突变的疗效上比传统敏感突变未见明显优势,但复合突变比单纯突变临床获益更多。
Objective: To investigate the clinical efficacy of icitin on EGFR 18 exon G719X / E709X / G724S in non-small cell lung cancer (NSCLC). Methods: A retrospective analysis of 24 patients with imatinib treatment of EGFR18 rare mutations in NSCLC patients, taking to the progression of the disease or intolerable side effects, the efficacy. Results: Of the 24 patients with G719X / E709X / G724S mutation, 19 patients had G719X mutation with a median progression-free survival time of 2.8 months, 3 patients with E709X mutation, 3.1% median progression-free survival time, 2 patients with G724S mutation, Progressive survival time of 3.5 months. G724S mutations in patients with longer survival time. Compound mutations Compared with simple mutations, the median progression-free survival time was longer for combined mutations (G719X mutation 3.3 months versus 2.6 months, P = 0.029; E709X mutation 7.2 months vs.2.7 months, P = 0.225). CONCLUSION: Icitinib has no obvious advantage over the traditional sensitive mutation in the rare mutation of exon 18 of EGFR gene, but the compound mutation has more clinical benefit than the simple mutation.